Search | Clinical Trials Finder

Conditions: Major Depressive Disorder
Interventions: Antidepressants through Texas Medication Algorithm (TMA), Brief Interpersonal Psychotherapy (IPT-B); Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 79 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Placebo, Antidepressant Therapy (ADT); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,022 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 83
States / cities: Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more

Conditions: Healthy Volunteers, Depression
Interventions: Magnetic Resonance Imaging scanner, 3T, NeurOptics PLRTM-3000 Pupillometer, Experimental Anxiety Devices, Magnetic Resonance Imaging scanner, 7T, Ketamine Hydrochloride; Device · Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Antenatal Depression, Major Depressive Disorder, Major Depressive Disorder in Pregnancy, Healthy Controls
Interventions: tACS (aperiodic); Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Major Depressive Disorder, Irritable Bowel Syndrome
Interventions: Ganeden BC30, Placebo (sugar pill), Ganeden BC30, Placebo (sugar pill); Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Burlington, Massachusetts • Westborough, Massachusetts

Conditions: Major Depressive Disorder
Interventions: ALKS 5461; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 123
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 105 more

Conditions: Amphetamine Abuse, Amphetamine Dependence, Bipolar Disorder, Major Depressive Disorder
Interventions: Citicoline, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depressive Disorder, Treatment Resistant Depression
Interventions: Personalized iTBS, Non-Personalized iTBS, Sham iTBS; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Major Depressive Disorder, MDD
Interventions: tACS, Sham tACS; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Major Depression, Mania, Anxiety Disorders, Psychotic Disorder, Alcohol Dependence, Drug Dependence, Eating Disorders, Suicidality, Dysthymia, ADHD, Tourettes Disorder, Conduct Disorder, Oppositional Defiant Disorder, Pervasive Developmental Disorder
Interventions: MINI-KID; Other
Lead sponsor: University of South Florida; Other
Eligibility: 6 Years to 17 Years
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Depression, Major Depressive Disorder, Suicidal Ideation
Interventions: Single-Pulse Transcranial Magnetic Stimulation, EEG-Synchronized Repetitive Transcranial Magnetic Stimulation (rTMS), Cognitive Behavioral Therapy (CBT), Cognitive Flexibility and Emotion Regulation Tasks; Device · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Major Depressive Disorder
Interventions: Transcranial direct current stimulation, Sham Transcranial direct current stimulation; Device
Lead sponsor: Flow Neuroscience AB; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
Interventions: olanzapine versus risperidone; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions: There is no intervention in this study; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: 12 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Major Depressive Disorder (MDD)
Interventions: Accelerated rTMS treatment; Device
Lead sponsor: NeuroQore Inc.; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: San Jose, California

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: OPC-34712 + ADT, Placebo + ADT; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 52
States / cities: Birmingham, Alabama • Costa Mesa, California • Glendale, California + 49 more

Conditions: Type 2 Diabetes, Major Depressive Disorder
Interventions: Diabetes and depression intervention, Diabetes intervention; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depression With Psychotic Features
Interventions: risperidone; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Current Major Depressive Disorder, Healthy, Remitted Major Depressive Disorder
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fibromyalgia, Chronic Pain, Depression
Interventions: rTMS, Sham rTMS; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Major Depressive Disorder
Interventions: Azetukalner, Placebo; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 45
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 38 more

Conditions: Depression
Interventions: Testosterone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Depression, Suicidal Ideation, Major Depressive Disorder, Depressive Disorder
Interventions: "Engage & Connect" Psychotherapy, Symptom Review and Psychoeducation (SRP); Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depression, Anxiety Disorder, Post-Traumatic Stress Disorder, Substance Abuse Disorder
Interventions: Photobiomodulation with a super-luminous light emitting diode; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

Neurobiology of Suicide

Pilot Study of Personalized Aperiodic Transcranial Alternating Current Stimulation in Antenatal Depression (PandA-tACS)

Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder

A Long-Term Safety Study of ALKS 5461

A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence

Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression

Mechanism of Action of tACS for the Treatment of MDD

Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

RECOVERS - Realigning Emotion and COgnition Via prEcision Regulation networkS

Empower: tDCS for Major Depressive Disorder at Home

Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NQ TMS for MDD Therapy Using 1 Day x 3 Sessions Protocol for Adult Patient

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)

A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care

Treatment of Major Depressive Disorder With Psychotic Features.

Evaluating Brain Responses to Facial Expressions in Major Depressive Disorder

Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

Testosterone Antidepressant Augmentation in Women

Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality

Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression